Long-Distance Delivery of Bacterial Virulence Factors by Pseudomonas aeruginosa Outer Membrane Vesicles

A Pseudomonas aeruginosa bacterium sits in the mucus-lined airways of a cystic fibrosis patient, never touching the epithelial cells below. And yet those cells are being poisoned. Within ten minutes of the bacterium's presence, toxins are appearing inside the host cell cytoplasm. The bacteria didn't move; they didn't need to. They sent something ahead — a tiny lipid sphere, pinched off from the bacterial outer membrane, drifting through the surrounding fluid until it fuses with the host cell wall and delivers its cargo directly inside. The weapon travels alone. That mechanism is what Bomberger and colleagues set out to document. What they found rewrites a model that had stood largely unchallenged for decades. The old assumption was straightforward: bacteria secrete virulence factors — toxic proteins that damage host tissue — and those proteins drift through the extracellular space until they randomly bump into a host cell surface. It's a diffusion model. Passive, uncoordinated, probabilistic. For Pseudomonas aeruginosa, an opportunistic pathogen that causes devastating lung disease in cystic fibrosis patients and accounts for a major share of the estimated ninety-nine thousand annual deaths from nosocomial infections in the U.S., researchers had catalogued four key secreted proteins: beta-lactamase, alkaline phosphatase, hemolytic phospholipase C, and a toxin called Cif, which inhibits a chloride channel called CFTR — the cystic fibrosis transmembrane conductance regulator. Reducing CFTR function in airway cells compromises mucociliary clearance, the lungs' primary mechanism for expelling pathogens. So Cif is not a trivial player. But the question the paper asks is whether naked diffusion is really how it gets delivered — because the numbers, when you look closely, don't support that picture at all. Outer membrane vesicles, or OMVs, are the alternative. These are small lipid spheres, ranging from fifty to two hundred nanometres across, that Gram-negative bacteria continuously pinch off from their outer membranes. They carry lipopolysaccharide, phospholipids, outer membrane proteins, and soluble proteins from the periplasm — the space between the bacterial inner and outer membranes. The team purified OMVs from Pseudomonas using differential centrifugation followed by a discontinuous Optiprep density gradient, which separates intact vesicles from contaminating structures like pili. The critical question was whether virulence factors like Cif were simply stuck to the outside of these vesicles or actually enclosed within them. Two experiments answered that. First, intact OMVs were treated with proteinase K, an enzyme that degrades proteins on the exterior of vesicles. Cif survived — meaning it was shielded from the enzyme, not surface-exposed. Second, the team lysed the vesicles with EDTA to break open the membranes, then applied proteinase K again. This time, Cif was degraded. That two-step result confirms that Cif is packaged inside the vesicle lumen, protected and ready for delivery. Being enclosed is not a trivial detail. It means the toxin arrives intact, folded, and enzymatically active — and it arrives in bulk, alongside other virulence factors, all at once. Now comes the delivery mechanism itself, and this is where the biology gets genuinely elegant. Bomberger and colleagues identified a two-step pathway. Step one: the OMV fuses specifically with lipid rafts in the host plasma membrane. Lipid rafts are cholesterol-rich microdomains — patches of the cell membrane with a distinct composition that act as organizing hubs for various cellular processes. After just five minutes of OMV exposure, both Cif and the OMV protein Omp85 were recovered in the lipid raft fraction of host cell membranes, co-fractionating with the raft marker flotillin-1. Imaging with rhodamine-labeled OMVs — a dye that fluoresces only when the vesicle membrane merges with another membrane — showed rapid co-localization with the lipid raft marker cholera toxin B subunit. The Pearson's correlation coefficient was zero point seventy-seven, compared to a control value of zero point fifteen. That's not a subtle shift. To prove the rafts are required, the team disrupted them. Pretreatment with Filipin three, which sequesters cholesterol and dismantles raft structure, abolished the OMV fusion signal entirely. It also blocked Cif from appearing in the host cell's endosomal fraction and prevented the downstream reduction of apical CFTR. No rafts, no delivery, no toxicity. Step two is actin. Once the OMV fuses with the lipid raft, the cargo doesn't just fall into the cell — it's actively moved inward by N-WASP-mediated actin polymerization. N-WASP is a protein that nucleates the growth of actin filaments, essentially building a mechanical scaffold that pulls vesicle contents into the cell interior. When the team blocked this step — either with cytochalasin D, which disrupts actin filaments, or with wiskostatin, which inhibits N-WASP directly — OMV fusion dropped significantly, Cif failed to appear in the cytoplasm, and the CFTR-reducing activity of Cif was abolished. The two steps are sequential. Raft fusion opens the gate; actin trafficking moves the cargo through. Where does the cargo go once it's inside? Cif, tracked as the model payload, localizes to the cytoplasmic face of early endosomes — not inside the endosomal lumen, but on the outer surface. The evidence: Cif co-immunoprecipitates with Rab5 and EEA-1, both established markers of early endosomes, and proteinase K treatment degrades Cif from the endosomal fraction — which would only happen if Cif is exposed on the cytoplasmic side, not tucked inside the endosome where the enzyme can't reach. This distinction matters because it tells you Cif is sitting where it can interact with cytoplasmic machinery, not trapped in a compartment headed for degradation. Blocking endosomal acidification with ammonium chloride or retrograde transport with Brefeldin A had no effect on Cif delivery or function — which rules out the idea that OMVs are just being endocytosed by the normal pathway and then escaping. The delivery is direct. Fusion, actin trafficking, cytoplasmic face of the early endosome. That's the route. And different cargo takes different routes. Hemolytic phospholipase C and alkaline phosphatase also ended up in endosomal fractions after OMV delivery. Beta-lactamase, by contrast, appeared in the cytoplasmic fraction. So the cargo isn't scattered randomly — it distributes to specific subcellular locations, which suggests an organized sorting process operating after cytoplasmic entry. The functional payoff of packaging matters enormously, and the paper states it with one number that is hard to move past. Three nanograms of Cif delivered inside intact OMVs reduced apical plasma membrane CFTR as effectively as fifty micrograms of purified recombinant Cif protein added directly to cells. That's a seventeen thousand-fold difference in efficacy. And at concentrations up to ten nanograms, recombinant Cif added without a vesicle couldn't be detected in cell lysates at all — meaning the naked protein wasn't getting in. Lysed OMVs, which release their contents without the intact vesicle structure, were dramatically less effective than intact OMVs. The vehicle is not incidental to the delivery. The vehicle is the delivery. Cytotoxicity told the same story. Intact OMV preparations caused significant host cell death after eight hours of exposure. Lysed OMV preparations did not. The enclosure, the fusion mechanism, the actin machinery — all of it is load-bearing. What this work establishes is that OMV-mediated secretion should be considered a bona fide secretion system, not a curiosity or a side channel. The paper tracked four virulence factors entering host cells simultaneously, each reaching specific intracellular destinations, none of it requiring the bacterium to be anywhere nearby. This is especially significant in chronic lung infections — cystic fibrosis, chronic obstructive pulmonary disease, bronchiectasis — where Pseudomonas often lives in biofilms embedded in mucus, physically separated from the epithelial cells it damages. The bacterium doesn't close that gap. It doesn't need to. OMV production has been documented across diverse Gram-negative species — Escherichia coli, Helicobacter pylori, Aggregatibacter actinomycetemcomitans, Vibrio cholerae, Neisseria meningitidis — suggesting that this delivery strategy is not a Pseudomonas quirk but a broadly conserved mechanism. The implications extend well beyond cystic fibrosis airways. And it opens a therapeutic angle that the random diffusion model never offered. If you target the individual toxin, you are playing whack-a-mole with a pathogen that packages dozens of factors simultaneously. But if the delivery vehicle itself is the mechanism — if the raft fusion or the N-WASP-mediated actin step is the bottleneck — then you have a single point of intervention that blocks everything at once. The bacterium stays where it is. The vesicles keep forming. But nothing gets through. This lecture was created by ennepō. Go to https://ennepo.ai to Discover, Create and Follow the latest research in your field. Read when you can. Listen when you want to.